Skip to main content
Premium Trial:

Request an Annual Quote

DNA Sciences, GlaxoSmithKline Study Links to Adverse Events

NEW YORK, June 17 - DNA Sciences and GlaxoSmithKline will collaborate to study SNPs related to certain drug-related adverse cardiovascular events, DNA Sciences said today.


Under the agreement, DNA Sciences will use its high-throughput sequencing and genotyping facility to study genetic variants that may predispose patients to so-called Long QT Syndrome, a potentially fatal adverse event brought on by more than 50 currently available medications.


Click here for more information.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.